Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).
Saved in:
| Title: | Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). |
|---|---|
| Authors: | Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. francesco.massari8@unibo.it.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. francesco.massari8@unibo.it., Fujita K; Department of Urology, Faculty of Medicine, Kindai University, Osaka, Japan., Giannatempo P; Dipartimento Di Oncologia Medica, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Büttner T; Department of Urology, University Hospital Bonn, Bonn, Germany., Bourlon MT; Department of Hemato-Oncology, Escuela de Medicina, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico-Universidad Panamericana, Mexico City, Mexico., Taha T; Royal Marsden NHS Foundation Trust, London, UK., Fukuokaya W; Department of Urology, Jikei University School of Medicine, Tokyo, Japan., Myint ZW; Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, USA., Pichler R; Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria., Binz K; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Kansas, USA., Molina-Cerrillo J; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Kopecky J; Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czechia., de Liaño AG; Medical Oncology Department, CHU Insular-Materno Infantil, Las Palmas, Spain., Kucharz J; Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland., Fiala O; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Matrana MR; Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA., Kopp RM; Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Di Civita MA; Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, University of Rome, Rome, Italy., Zgura A; Department of Obstetrics-Radiotherapy, Alexandru Trestioreanu Institute of Oncology, 'Carol Davila' University of Medicine and Pharmacy, Prof. Dr, Bucharest, Romania., Ansari J; Medical Oncology, Tawam Hospital, Al Ain, UAE., Kihnel R; Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA., De Felice F; Radiation Oncology, Department of Radiological, AOU Policlinico Umberto I, Oncological and Pathological Sciences, 'Sapienza' University of Rome, Rome, Italy., Angel M; Instituto Alexander Fleming, Ciudad De Buenos Aires, Argentina., Monteiro FSM; Latin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil.; Oncology and Hematology Department, Hospital Sírio Libanês, Brasília, Brazil., Soares A; Latin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil.; Oncology Unit, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Urun Y; Department of Medical Oncology, Faculty of Medicine, Ankara University, 06620, Ankara, Turkey., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Santini D; Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, University of Rome, Rome, Italy., Santoni M; Medical Oncology Unit, Macerata Hospital, Macerata, Italy. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Mar 24; Vol. 75 (4). Date of Electronic Publication: 2026 Mar 24. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-026-04328-9 |
